MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine the safety and tolerability of the novel compound,
MRx0518 in patients with solid tumours at 30 days post-surgery.
20 participants will receive open label MRx0518 in a preliminary safety phase. After
successful evaluation by the Independent Safety Monitoring Committee (IDMC), a further 100
participants will be recruited to receive MRx0518/Placebo.